The CYP2D6*10 genotype is associated with lower levels of active metabolites of tamoxifen in Asian breast cancer patients, which may impact the clinical effectiveness of tamoxifen31, 32, 33 and had poor prognosis.9 This evidence concerns the gene CYP2D6 and breast cancer.